Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 1/2 Completed New Approaches to Brain Tumor Therapy Consortium National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent malignant glioma.

Timeline

Start: 1998-07
Primary completion: —
Completion: 2004-04

Publications

Results Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S; NABTT CNS Consortium. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004 Jan;6(1):21-7. doi: 10.1215/s1152851703000218.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	—	Intravenous

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications